Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
6.55
-0.04 (-0.61%)
Aug 26, 2026, 12:12 PM EDT - Market open
Prelude Therapeutics Revenue
Prelude Therapeutics had revenue of $5.70M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $22.42M, up 220.34% year-over-year. In the year 2025, Prelude Therapeutics had annual revenue of $12.14M with 73.43% growth.
Revenue (ttm)
$22.42M
Revenue Growth
+220.34%
P/S Ratio
30.27
Revenue / Employee
$283,848
Employees
79
Market Cap
674.62M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.14M | 5.14M | 73.43% |
| Dec 31, 2024 | 7.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 462.25M |
| Phathom Pharmaceuticals | 239.66M |
| Valneva SE | 163.30M |
| Zevra Therapeutics | 136.07M |
| Verastem | 87.53M |
| OmniAb | 38.46M |
PRLD News
- 15 days ago - Prelude Therapeutics Earnings release: Q2 2026 - Filings
- 15 days ago - Prelude Therapeutics Quarterly report: Q2 2026 - Filings
- 15 days ago - Prelude Therapeutics reports Q2 EPS (14c), consensus (19c) - TheFly
- 16 days ago - Prelude Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline - TheFly
- 2 months ago - Prelude Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Prelude Therapeutics Transcript: AGM 2026 - Transcripts
- 3 months ago - Prelude Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts